VistaGen Therapeutics Reports Phase 3 Trial of Fasedienol for Social Anxiety Disorder Fails to Meet Primary Endpoint

Reuters2025-12-17

VistaGen <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Phase 3 Trial of Fasedienol for Social Anxiety Disorder Fails to Meet Primary Endpoint

VistaGen Therapeutics Inc. announced topline results from the PALISADE-3 Phase 3 clinical study evaluating intranasal fasedienol for the acute treatment of social anxiety disorder. The study did not demonstrate a statistically significant improvement on the primary endpoint, as measured by the Subjective Units of Distress Scale (SUDS), with results showing no significant difference between fasedienol and placebo. No treatment difference was observed for secondary endpoints. The safety profile of fasedienol remained favorable and consistent with previous clinical trials. The results of the study have already been presented. VistaGen is reviewing the results, assessing their impact on ongoing studies, and plans to consult with the FDA while implementing cash preservation measures to extend its operational runway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217824138) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592913918?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592913918","market":"us","top_or_hot":-1,"title":"VistaGen Therapeutics Reports Phase 3 Trial of Fasedienol for Social Anxiety Disorder Fails to Meet Primary Endpoint","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VistaGen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 3 Trial of Fasedienol for Social Anxiety Disorder Fails to Meet Primary Endpoint\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VistaGen Therapeutics Inc. announced topline results from the PALISADE-3 Phase 3 clinical study evaluating intranasal fasedienol for the acute treatment of social anxiety disorder. The study did not demonstrate a statistically significant improvement on the primary endpoint, as measured by the Subjective Units of Distress Scale (SUDS), with results showing no significant difference between fasedienol and placebo. No treatment difference was observed for secondary endpoints. The safety profile of fasedienol remained favorable and consistent with previous clinical trials. The results of the study have already been presented. VistaGen is reviewing the results, assessing their impact on ongoing studies, and plans to consult with the FDA while implementing cash preservation measures to extend its operational runway.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217824138) on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VistaGen Therapeutics Reports Phase 3 Trial of Fasedienol for Social Anxiety Disorder Fails to Meet Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVistaGen Therapeutics Reports Phase 3 Trial of Fasedienol for Social Anxiety Disorder Fails to Meet Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      VistaGen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Phase 3 Trial of Fasedienol for Social Anxiety Disorder Fails to Meet Primary Endpoint\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        VistaGen Therapeutics Inc. announced topline results from the PALISADE-3 Phase 3 clinical study evaluating intranasal fasedienol for the acute treatment of social anxiety disorder. The study did not demonstrate a statistically significant improvement on the primary endpoint, as measured by the Subjective Units of Distress Scale (SUDS), with results showing no significant difference between fasedienol and placebo. No treatment difference was observed for secondary endpoints. The safety profile of fasedienol remained favorable and consistent with previous clinical trials. The results of the study have already been presented. VistaGen is reviewing the results, assessing their impact on ongoing studies, and plans to consult with the FDA while implementing cash preservation measures to extend its operational runway.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217824138) on December 17, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL2CVTRT:1","article_id":"2592913918","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592913918","pubTimestamp":1765978247,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"VistaGen Therapeutics Inc. announced topline results from the PALISADE-3 Phase 3 clinical study evaluating intranasal fasedienol for the acute treatment of social anxiety disorder. The study did not demonstrate a statistically significant improvement on the primary endpoint, as measured by the Subjective Units of Distress Scale , with results showing no significant difference between fasedienol and placebo. No treatment difference was observed for secondary endpoints. The safety profile of fasedienol remained favorable and consistent with previous clinical trials. The results of the study have already been presented. VistaGen is reviewing the results, assessing their impact on ongoing studies, and plans to consult with the FDA while implementing cash preservation measures to extend its operational runway.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VTGN":"VistaGen Therapeutics, Inc."},"translate_title":"VistaGen Therapeutics报告Fasedienol治疗社交焦虑症的3期试验未能达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTGN":0.9},"content_text":"VistaGen Therapeutics Reports Phase 3 Trial of Fasedienol for Social Anxiety Disorder Fails to Meet Primary Endpoint\n    \n\n        VistaGen Therapeutics Inc. announced topline results from the PALISADE-3 Phase 3 clinical study evaluating intranasal fasedienol for the acute treatment of social anxiety disorder. The study did not demonstrate a statistically significant improvement on the primary endpoint, as measured by the Subjective Units of Distress Scale (SUDS), with results showing no significant difference between fasedienol and placebo. No treatment difference was observed for secondary endpoints. The safety profile of fasedienol remained favorable and consistent with previous clinical trials. The results of the study have already been presented. VistaGen is reviewing the results, assessing their impact on ongoing studies, and plans to consult with the FDA while implementing cash preservation measures to extend its operational runway.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251217824138) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592913918","isCrawlerRequest":true}